A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma Aims: CDX2 is widely used as a sensitive and specific immunomarker for colorectal carcinoma (CRC), but neither its sensitivity nor its specificity is absolute. The aim of this study was to compare CDX1 and A33 with CDX2 as immunomarkers for CRC. Methods and results: As a pilot study, whole sections of 51 cases of liver metastatic carcinoma with different origins-colorectum (n = 32), breast (n = 3), oesophagogastric tract (n = 4), lung (n = 3), pancreas (n = 8), and prostate (n = 1)-were immunostained with CDX1, CDX2, and A33. A33 showed higher sensitivity as a CRC immunomarker, greater interobserver reproducibility for assessment of expression and less background cross-reactivity than CDX1. Therefore, only A33 was compared with CDX2 for a tissue microarray (TMA)-based study of primary adenocarcinomas with different origins: CRC (n = 55), liver deposits of metastatic CRC (n = 60), breast (n = 101), lung (n = 40), oesophagogastric tract (n = 134), ovary (n = 67), pancreas (n = 77), and prostate (n = 56). When the whole section and TMA cases of CRC were combined, A33 had a sensitivity of 95.9% and CDX2 had a sensitivity of 97.2%. When the whole section and TMA cases of non-colorectal carcinomas were combined, A33 had a specificity of 85.4% as a marker of CRC and CDX2 had a specificity of 64.3%. The higher specificity of A33 than of CDX2 as a CRC immunomarker was particularly seen among pancreatic and ovarian carcinomas. Furthermore, unlike what was seen with CDX2, none of the prostatic and lung carcinomas studied showed A33 positivity. Conclusions: A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of CRC.
Introduction
Carcinoma of unknown primary (CUP) is a common clinical and diagnostic problem.
1,2 A common presentation of CUP is as liver metastases. 1, 2 Determining the primary neoplasm site giving rise to these metastases has important oncological management implications, especially in the era of personalized medicine. For example, if the carcinoma is of colorectal origin and does not harbour RAS mutations, antiepidermal growth factor receptor therapy becomes a potential management option. 3 Apart from radiological and endoscopic investigations, the main way in which cases of CUP are further investigated is tissuebased. 1, 2 This involves morphological assessment of a biopsy of the metastasis and, in particular, immunohistochemical analysis of the carcinoma. 1 It is standard practice to apply a panel of antibodies to CUP tissue to help determine its likely site of origin. 1 As a specific and sensitive immunomarker for colorectal carcinoma (CRC), CDX2 is one of the most commonly used immunostains in the investigation of CUP. 1 Nonetheless, its sensitivity has been recorded to range from 100% to 71%; [4] [5] [6] [7] poorly differentiated CRC, in particular, may lack CDX2 expression. 4, 5 Furthermore, it is now well recognized that CDX2 expression may been seen in a varying proportion of pancreaticobiliary, ovarian and, particularly, oesophagogastric carcinomas, and even, rarely, in lung and prostatic carcinomas. [4] [5] [6] [7] One of the study authors previously investigated the roles of CDX2 and CDX1 in the pathogenesis of Barrett's metaplasia, and also the potential for A33 to serve as a marker of such metaplasia. 8, 9 The similarity of CDX1 to CDX2 as a homeobox protein regulating intestinal differentiation 10, 11 suggests that the former may also serve as an immunomarker for CRC. Bai et al. 12 raised their own monoclonal antibody against CDX1, but only tested it in gastric carcinomas. Similarly, only gastric carcinomas were studied in a later study that used a polyclonal CDX1 antibody. 13 The facts that CDX1 may regulate A33 (also known as gpA33) expression 11 and that physiological expression of A33 is almost entirely limited to intestinal epithelium 14, 15 suggest that A33 might also serve as an immunomarker for CRC. Indeed, haemagglutination testing of an early A33 antibody (clone mAbA33) in cancer cell lines showed reactivity in several CRC cell lines, in one of three pancreatic carcinoma cell lines, and in one of 24 lung carcinoma cell lines, but not in any ovarian or breast carcinoma cell lines. 16 Sakamoto et al. 16 also studied A33 expression in gastric carcinomas, but not in any other carcinoma sites. Using the same antibody, an earlier study published in 1996 recorded A33 expression in 95% of CRCs and in at least 50% of gastric and pancreatic carcinomas, but in <10% of breast and ovarian carcinomas. 14 We are unaware of any subsequently published data on A33 immunopositivity among a range of adenocarcinomas from different organs.
Our previous intentions to study CDX1 and A33 as immunomarkers for CRC were hampered by the limited availability of monoclonal antibodies against the proteins that could be applied successfully to immunohistochemistry. More recently, however, the previous laboratory of one of the study authors has successfully raised a monoclonal antibody against CDX1, 17 and there are now commercial A33 monoclonal antibodies marketed for immunohistochemical use. The current study therefore represents the first known attempt to systematically compare CDX1 and A33 with CDX2 as immunomarkers of CRC.
Materials and methods
Two cohorts of different samples were used. The initial pilot study used anonymized tissue samples that had been compiled and analysed in a previous morphology-based study. 18 All of these cases were liver metastases from known or subsequently established sites of origin. 18 These cases had all been collected from the files of the Department of Histopathology at the Bristol Royal Infirmary, and all yielded whole tissue sections for immunohistochemistry. The second cohort of tissue samples were all tissue microarray (TMA) sections. These TMA sections were derived from either the National Health Service Greater Glasgow and Clyde Bio-Repository in Glasgow or the Department of Pathology at the Royal Infirmary of Edinburgh. Each TMA represented primary adenocarcinoma from one particular anatomical site, i.e. breast, lung, ovary, oesophagogastric tract, pancreas, prostate, or colorectum. Furthermore, the primary CRC cases had a paired TMA of matched liver metastases. This study and its use of all these anonymized tissue samples had received research ethics committee approval (REC Oxford South Central; reference number 14/SC/0155; 11 December 2015).
All immunohistochemistry was performed with the Leica Bond III automated immunostainer (Leica Biosystems, Newcastle upon Tyne, UK) using the Bond polymer refine kit detection system (Leica Biosystems). The CDX1 monoclonal antibody (obtained from the Cancer and Immunogenetics Laboratory, Oxford, UK) was used at a 1:200 dilution (incubation period of 12 min) after heat pretreatment with Bond epitope retrieval solution 2 (Leica) for 20 min. The CDX2 monoclonal antibody (clone EP25; Leica Biosystems) was used commercially prediluted (incubation period of 15 min) after heat pretreatment with Bond epitope retrieval solution 2 (Leica Biosystems) for 20 min. The A33 monoclonal antibody (clone EPR4240; Epitomics/Abcam, Cambridge, UK) was used at a 1:250 dilution (incubation period of 15 min) after heat pretreatment with pH 6 citrate buffer for 20 min. A positive control (of normal large bowel wall including mucosa) was run with each round of each antibody.
Both the whole tissue sections and the TMA sections were scored for intensity and proportion of immunopositivity. Intensity was scored as absent, strong (equivalent intensity to the positive control tissue), or weak (any intensity below that of the positive control tissue). For the whole tissue sections, the proportion of positivity was scored according to a five-point scale: 0 (0%); 1 (1-25%); 2 (26-50%); 3 (51-75%); and 4 (76-100%). For the TMA sections, the proportion of positivity was scored according to a three-point scale: 0 (0%); 1 (1-50%); and 2 (51-100%). The immunostained whole tissue sections were assessed independently by two observers (N.W. and J.C. for CDX1 and CDX2; N.W. and S.E. for A33), and the immunostained TMA sections were assessed by one observer (N.W.).
Results
In normal large bowel wall and all of the tested tissues (both whole tissue sections and TMA sections), A33 showed only membranous positivity. In the normal large bowel wall, this positivity was restricted to crypt and surface epithelium (diffusely throughout the entire length of the crypt), and was not seen in any other cell type. There was no A33 positivity in submucosal or deeper tissues.
CDX1 positivity in non-neoplastic intestinal epithelium and in most carcinomas (see below) had a nuclear location ( Figure 1 ). Rarely (see below), CDX1 positivity in carcinomas had a membranous location instead ( Figure 1 ). In the positive control and the test cases, CDX1 immunohistochemistry often showed cytoplasmic positivity in smooth muscle (muscularis mucosae, muscularis propria, and vascular media) and in myofibroblasts ( Figure 1 ).
Fifty-one cases of liver metastatic carcinoma (see Table 1 for primary sites of origin) were used for the pilot study involving immunohistochemistry for CDX1, CDX2, and A33. Among these 51 whole tissue sections, there was 100% concordance between two independent assessors when recording the presence (defined as strong-intensity or weak-intensity positivity) versus absence of immunopositivity for A33. Similar assessment of the CDX1-immunostained sections yielded two cases with discordant findings (i.e. presence versus absence of positivity) between two assessors, and similar assessment of the CDX2-stained sections yielded one case with discordant findings between two assessors. Table 1 shows the sensitivities and specificities of A33, CDX2 and CDX1 as immunomarkers of CRC, derived from this pilot study of 51 cases.
The non-colorectal carcinomas that most commonly showed positivity for all three antibodies were derived from the pancreas or the oesophagogastric tract (Table 1) . Whereas only one pancreatic carcinoma showed CDX1 nuclear positivity, four other pancreatic carcinomas showed membranous CDX1 positivity ( Figure 1 ). Such membranous location of CDX1 positivity was not seen in any of the other carcinomas in this pilot study cohort.
CDX1 was abandoned and only A33 was compared with CDX2 for the TMA-based analysis, for several reasons related to these pilot study data. First, the interobserver reproducibility for A33 assessment was higher than that for CDX1. Second, this reproducibility difference may have been related to the much cleaner immunohistochemical staining of A33 (than of CDX1) and/or the apparent crossreactivity of the CDX1 antibody with smooth muscle. Third, A33 showed equivalent sensitivity as a CRC immunomarker to CDX2, and such sensitivity was higher than for CDX1. Fourth, the fact that A33 positivity had a membranous location (in contrast to the nuclear location of CDX1 positivity) opened the possibility for combined immunostaining with both A33 and CDX2, e.g. using dual labelling. As a final note, it is worth acknowledging data showing that CDX1 regulates A33 expression 11 and that A33 can therefore serve as a surrogate for CDX1 expression.
A B Figure 1 . CDX1 immunohistochemistry of (A) colorectal carcinoma and (B) pancreatic ductal carcinoma. Whereas the colorectal carcinoma shows only nuclear positivity, decoration of vascular media (arrowhead) and myofibroblasts (arrows) of the desmoplastic stroma had a cytoplasmic location. The pancreatic carcinoma was one of four (of eight pancreatic carcinomas studied) that showed striking membranous CDX1 positivity; this cellular location of positivity was not seen among carcinomas from any other site of origin.
A33 and CDX2 immunohistochemistry was performed on sections cut from eight TMA blocks (Table 1) . Two blocks represented primary CRC and liver deposits of metastatic CRC. Between these two TMA blocks, there were a total of 39 matched primary and secondary CRC tissues.
When the liver metastatic CRC cases (whole section and TMA sections; Table 1 ), were combined, both A33 and CDX2 showed identical sensitivity as a marker of CRC, i.e. 96.7% (Figure 2) . The same two cases of liver metastatic CRC were negative for A33 and CDX2. When the primary CRC cases were combined with the liver metastatic cases (total of 147 specimens, including 39 matched primary and secondary specimens), A33 had a sensitivity of 95.9% and CDX2 had a sensitivity of 97.2%.
Of 30 whole tissue sections of metastatic CRC that showed A33 positivity and CDX2 positivity, only one case showed weak-intensity A33 positivity and only one case showed weak-intensity CDX2 positivity, but four cases showed <50% A33 positivity and only one case showed <50% CDX2 positivity. Of the 59 TMA cases of metastatic CRC showing A33 positivity and CDX2 positivity, two and no cases showed weakintensity positivity for A33 and CDX2, respectively, whereas 14 and three cases showed <50% positivity for A33 and CDX2, respectively. Of the 39 cases of matched primary and metastatic CRC in the TMA cases, all 39 pairs showed CDX2 positivity in both primary and metastatic tissue, and all but one case showed A33 positivity in both primary and metastatic tissue. The discordant A33 case showed positivity in the primary neoplasm but not in its matched metastatic tissue.
When non-colorectal adenocarcinoma cases from the whole section specimens and the TMA specimens were combined (Table 1) , A33 showed a specificity of 85.4% as a marker of CRC, and CDX2 showed a specificity of 64.3%. When oesophagogastric carcinomas were re-categorized for analysis, A33 showed a specificity of 97.8% as a marker of carcinoma arising from the tubular gastrointestinal tract, and CDX2 showed a specificity of 79.5%. The differences in specificity were mainly attributable to the rarity of A33 positivity among pancreatic and ovarian carcinomas as compared with CDX2 positivity (Figure 2) . However, and in addition, CDX2 positivity was occasionally seen in prostatic and lung carcinomas, whereas all of these carcinomas studied were negative for A33 (Figure 2) .
Discussion
This study has demonstrated that A33 is a more specific immunomarker than CDX2 for CRC.
We considered whether this higher specificity was attributable only to lower sensitivity. Among the primary CRC tissue in the TMA block, there were two cases that were CDX2-positive but A33-negative. Furthermore, the proportions of CRC cells showing A33 positivity were generally lower than those showing CDX2 positivity. This difference in proportions was more apparent in the TMA cores and less striking in whole tissue sections, but it is acknowledged that diagnostic immunomarkers for CUP are more commonly applied to biopsies and aspirates 1 rather than large resection-derived whole tissue sections. Finally, in contrast to CDX2, which showed complete concordance of staining among 39 pairs of matched primary and metastatic CRCs, one case showed A33 positivity in the primary carcinoma but not in the matched metastatic tissue. Nonetheless, and despite all of the above, both in the whole section cases and in the TMA cases of liver metastatic CRC, A33 still showed an overall identical sensitivity to that of CDX2. In conclusion, although the sensitivity of A33 might be, at most, marginally less than that of CDX2, this was not demonstrated in metastatic CRC, and we regard this potential difference as being too small to completely explain the higher specificity shown by A33.
We also considered whether the higher specificity of A33 might be attributable to erroneously higher CDX2-positive rates being recorded among our noncolorectal carcinomas. However, our proportions of CDX2-positive non-colorectal carcinoma cases were comparable to previously published data: 75% of our oesophagogastric adenocarcinomas as compared with 
70%
7 and 70%; 6 38% of our pancreatic adenocarcinomas as compared with 32% 7 and 50%; 6 9% of our prostatic adenocarcinomas as compared with 4% 7 and 2%; 6 and 7% of our lung adenocarcinomas as compared with 0% 7 and 6%. 6 Werling et al.
7
recorded CDX2 positivity in nine of 14 (64%) mucinous ovarian carcinomas and in none of 36 nonmucinous ovarian carcinomas, whereas Moskaluk et al. 6 recorded CDX2 positivity in one of four (25%) mucinous ovarian carcinomas and in six of 55 (11%) non-mucinous ovarian carcinomas. It is more difficult to compare our 49% CDX2 positivity rate among ovarian carcinomas with these published data, because our TMA cases were not further subtyped. However, the fact that a large proportion of our TMA ovarian cases were CDX2-positive suggests that many were likely to be mucinous carcinomas.
As an immunomarker of CRC tested in the pilot study, CDX1 showed similar specificity to that of A33, but less sensitivity than those of A33 and CDX2. Even if the tested CDX1 antibody were to be further assessed for diagnostic use, its apparent crossreactivity with smooth muscle would still have to be addressed. Indeed, the overall much cleaner staining of the A33 antibody tested would currently favour it for diagnostic use over the CDX1 antibody. The membranous CDX1 positivity shown by a proportion of our pancreatic carcinomas is a novel finding. However, applying this to diagnostic practice may be limited by potential confusion between this membranous staining and the cross-reacting cytoplasmic staining shown by the CDX1 antibody.
The superiority of A33 to CDX2 as a specific immunomarker for CRC was seen primarily among pancreatic and ovarian carcinomas. We often found CDX2 positivity to be weaker and/or more focal in pancreatic and ovarian cancers than in CRC (data not shown). However, in diagnostic practice and in our experience, it is challenging to use these more subjective assessments of proportion and/or intensity of immunopositivity to confidently subtype CUP. Our A33 expression profile among adenocarcinomas with different origins is similar to that recorded by Garincesha et al., 14 apart from their pancreatic carcinoma data. It is difficult to be certain why A33 expression was found in 50% of their pancreatic carcinomas 14 as compared with only 4% of our pancreatic carcinomas. The earlier study used a mouse monoclonal antibody on presumed whole tissue sections from frozen samples, 14 whereas we used a rabbit monoclonal antibody on a TMA prepared from formalin-fixed paraffin-embedded blocks. However, these differences are unlikely to explain a differential staining pattern only for pancreatic carcinomas and not for carcinomas of other organ sites. The exact A33 epitopes used to raise the two antibodies are not known or have not been published, precluding a direct comparison of the two antibodies. However, it may be of relevance that the earlier A33 antibody was raised through inoculation of a BALB/c mouse with the ASPC-1 pancreas cancer cell line and SP2/0 myeloma cells. 14 The few reported studies of A33 expression in human and murine physiological tissues have never mentioned any expression in the normal pancreas. 14, 15 One of these studies reported that 'areas of reactive normal pancreatic ducts adjacent to the pancreatic cancers also showed scattered A33+ epithelial cells', but it may be speculated that these areas were, in fact, foci of pancreatic intraepithelial neoplasia (PanIN). In contrast, multiple studies have described CDX2 expression by at least a subset of pancreatic ductal cells. [5] [6] [7] This difference in physiological expression may, at least in part, explain why A33 is less often expressed by pancreatic carcinomas than CDX2. Pancreatic adenocarcinomas (usually referred to as ductal carcinomas) are thought to arise from PanIN, intraductal papillary mucinous neoplasm, or, more rarely, mucinous cystic neoplasm. 19 Therefore, it would be interesting to determine what proportions of these precursor lesions express CDX2 versus A33.
The fact that A33 and/or CDX2 are expressed by a large proportion of oesophagogastric adenocarcinomas is not surprising, as many of these tumours arise on a background of intestinal metaplasia (in atrophic gastritis) or Barrett's metaplasia. 20, 21 Our proportion of A33-positive oesophagogastric adenocarcinomas (46%) was similar to the proportions of gastric carcinomas previously reported to express A33, i.e. 45% 16 and 58%. 14 The fact that a proportion of oesophagogastric carcinomas may arise instead from non-intestinal precursor lesions (e.g. foveolar-type dysplasia) 22 might explain why a proportion of these neoplasms do not express A33 and/or CDX2. However, it is still difficult to explain why a lower proportion of these carcinomas express A33 than express CDX2. CDX2 is not known to be expressed by physiological gastric mucosa 5, 6 and, if anything, it is more controversial whether or not A33 is expressed in such mucosa. In mice, A33 has been demonstrated along the entire gastric gland, although only in the pylorus. 15 One of this study's authors previously demonstrated A33 mRNA in one of four body gastric biopsies, 9 but it is conceivable that that particular biopsy included intestinal metaplasia. Furthermore, Sakamoto et al. 16 reported no A33 immunostaining in 38 cases of 'foveolar epithelium and gastric glands'.
Further lines of research are required to clarify the preliminary data of this study, and also to explore more specific questions raised by these data. It is the mucinous variant of ovarian carcinoma that is most difficult to distinguish from gastrointestinal carcinoma, including CRC. 1 Although many of our TMA ovarian carcinomas were likely to be mucinous (for the reasons explained above), a more targeted analysis of only primary ovarian mucinous carcinoma with A33 is required. Another diagnostic scenario that can be periodically challenging is the distinction between CRC and primary bladder adenocarcinoma, particularly as the latter can show CDX2 expression. 7 It has been suggested that b-catenin immunohistochemistry (nuclear decoration seen only in CRC 23 ) may help in making this distinction, but whether A33 may also aid in this distinction should be investigated next. Finally, larger cohorts of CRC from other centres should also be studied with A33, particularly to confirm the immunomarker's sensitivity, especially in biopsy material. One particular cohort worth studying comprises CDX2-negative CRCs, which may represent a specific subgroup with a poorer prognosis. 24 Although we accept that these are only limited data, the three CDX2-negative CRCs in our study cohort all also lacked A33 expression.
Although further research is required, this study's data show great promise for A33 as both a sensitive and a more specific marker of CRC than CDX2. Therefore, A33 may serve at least as an adjunct to CDX2 in the immunohistochemical panel used routinely to investigate CUP.
